SCHEMBL1008243

SCHEMBL1008243

CCOC(=O)Cc1cccc(OCc2ccc(C(F)(F)F)cc2)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 9/20 0.61
SLC2A1 P11166 1/20 0.51
MRGPRX4 Q96LA9 2/20 0.50
MAOA P21397 1/20 0.50
NR4A2 P43354 2/20 0.49
PTPN2 P17706 1/20 0.49
PTPN1 P18031 1/20 0.49
PTPRB P23467 1/20 0.49
PTPN6 P29350 1/20 0.49
PTPN11 Q06124 1/20 0.49
PPARG P37231 2/20 0.48
PPARA Q07869 2/20 0.48
LTB4R Q15722 1/20 0.47
LTB4R2 Q9NPC1 1/20 0.47
NR4A1 P22736 1/20 0.47
NR4A3 Q92570 1/20 0.47
FFAR2 O15552 1/20 0.47
SPHK2 Q9NRA0 1/20 0.47
SPHK1 Q9NYA1 1/20 0.47
PPARD Q03181 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1008116 0.86 LTB4R (0.61) MAOBMAOANR4A2PPARGPPARA
SCHEMBL3079913 0.85 MAOB (0.47) MAOBMRGPRX4NR4A2PPARGPPARA
SCHEMBL8046561 0.84 MAOB (0.48) MAOBPTPN1PPARGPPARAPPARD
SCHEMBL1010424 0.84 MAOB (0.64) MAOBSLC2A1MRGPRX4NR4A2PTPN2
SCHEMBL136924 0.83 RXRA (0.47) MAOBMRGPRX4NR4A2LTB4RLTB4R2
SCHEMBL477855 0.83 PSEN1 (0.60) MRGPRX4PTPN2PTPN1PTPN6PPARG
SCHEMBL2088046 0.82 MAOB (0.66) MAOBSLC2A1MRGPRX4MAOANR4A2
SCHEMBL1009050 0.81 MAOB (0.51) MAOBMAOAPPARGPPARALTB4R
SCHEMBL701131 0.81 ALDH1A1 (0.61)
SCHEMBL19685525 0.81 MAOB (0.63) MAOBSLC2A1MRGPRX4MAOANR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3517109-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2019-07-31 EP disclosed
EP-2268141-B1 COMPOUND AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORP (US) 2019-05-08 EP disclosed
US-9115072-B2 Compounds and method for reducing uric acid WELLSTAT THERAPEUTICS CORPORATION (US) 2015-08-25 US disclosed
CN-101969773-B compounds and methods for reducing uric acid WELLSTAT THERAPEUTICS CORP. (US) 2015-08-19 CN disclosed
CN-102976928-B Compounds for reducing uric acid WELLSTAT THERAPEUTICS CORP 2014-09-17 CN disclosed
US-8829058-B2 Compounds and method for reducing uric acid WELLSTAT THERAPEUTICS CORPORATION (US) 2014-09-09 US disclosed
US-20130259850-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2013-10-03 US disclosed
CN-102976928-A Compounds for reducing uric acid WELLSTAT THERAPEUTICS CORP 2013-03-20 CN disclosed
CN-101969773-A compounds and methods for reducing uric acid WELLSTAT THERAPEUTICS CORP 2011-02-09 CN disclosed
EP-2268141-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2011-01-05 EP disclosed
WO-2009151695-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130259850-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID RCC2, HAX1, SLC10A6 MAOB 3406/4885SLC2A1 496/4885MRGPRX4 1727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.